Chemomab Therapeutics Net Income Over Time
| CMMB Stock | USD 1.51 0.03 2.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Chemomab Therapeutics Performance and Chemomab Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. Projected growth potential of Chemomab fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Chemomab Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Chemomab Therapeutics's market price often diverges from its book value, the accounting figure shown on Chemomab's balance sheet. Smart investors calculate Chemomab Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Chemomab Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Chemomab Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Chemomab Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Chemomab Therapeutics and related stocks such as Kazia Therapeutics, Ocean Biomedical, and Theriva Biologics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KZIA | (17.1 M) | 1.3 M | (1 M) | (7.5 M) | (7.1 M) | (12.1 M) | (10.7 M) | (6 M) | (10.3 M) | (12.5 M) | (8.4 M) | (25 M) | (20.5 M) | (26.8 M) | (20.7 M) | (23.8 M) | (25 M) |
| TOVX | (3.9 M) | (8.1 M) | (17.1 M) | (12.3 M) | (19.8 M) | (43.7 M) | (27.3 M) | (15.2 M) | (13.4 M) | (15.3 M) | (10 M) | (14.2 M) | (19.7 M) | (18.3 M) | (25.7 M) | (23.1 M) | (21.9 M) |
| ELAB | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (784.7 K) | (1.8 M) | (4.3 M) | (6.2 M) | (5.6 M) | (5.3 M) |
| CANF | (3.7 M) | (6.7 M) | (5.6 M) | (8.3 M) | (6.1 M) | (4.8 M) | (6.9 M) | (5 M) | (6.6 M) | (12.6 M) | (14.4 M) | (12.6 M) | (10.2 M) | (7.6 M) | (7.9 M) | (7.1 M) | (7.4 M) |
| BIVI | (70 K) | (70 K) | (70 K) | (321.9 K) | (233 K) | (431.9 K) | (1.3 M) | (2.4 M) | (2.4 M) | (16.7 M) | (130.2 M) | (26.1 M) | (50.3 M) | (32.1 M) | (17.5 M) | (15.8 M) | (16.6 M) |
| XRTX | (36.9 K) | (36.9 K) | (36.9 K) | (36.9 K) | (36.9 K) | (414.8 K) | (414.8 K) | (474.2 K) | (3.8 M) | (485.5 K) | (1 M) | (1.3 M) | (7 M) | (2.2 M) | (4.8 M) | (4.3 M) | (4.1 M) |
| INM | (4.3 M) | (189.9 K) | (46.7 K) | (1.2 M) | (3.5 M) | (1.8 M) | (3.4 M) | (6.7 M) | (10 M) | (8.9 M) | (12.6 M) | (18.6 M) | (7.9 M) | (7.7 M) | (8.2 M) | (7.3 M) | (7 M) |
| CERO | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (667.7 K) | (2.5 K) | (7.7 M) | (7 M) | (6.6 M) |
| GLMD | (3.1 M) | (3.1 M) | (3.1 M) | (17.5 M) | (9.1 M) | (10.6 M) | (17 M) | (12.3 M) | (9.9 M) | (18.5 M) | (27.6 M) | (31.9 M) | (18.6 M) | (6.9 M) | (7.5 M) | (6.8 M) | (7.1 M) |
Chemomab Therapeutics and related stocks such as Kazia Therapeutics, Ocean Biomedical, and Theriva Biologics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Chemomab Therapeutics financial statement analysis. It represents the amount of money remaining after all of Chemomab Therapeutics Ltd operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Chemomab Therapeutics Ltd | CMMB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Building 7, Tel |
| Exchange | NASDAQ Exchange |
USD 1.51
Check out Chemomab Therapeutics Performance and Chemomab Therapeutics Correlation. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Chemomab Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.